About NewLimit
NewLimit is a company based in San Francisco (United States) founded in 2022 by Jacob Kimmel, Brian Armstrong, and Blake Byers. NewLimit has raised $247.25 million across 3 funding rounds from investors including Kleiner Perkins, Khosla Ventures and Dimension Venture Partners. The company has 9 employees as of October 31, 2024. NewLimit offers products and services including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program. NewLimit operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, CatSci and NIH, among others.
- Headquarter San Francisco, United States
- Employees 9 as on 31 Oct, 2024
- Founders Jacob Kimmel, Brian Armstrong, Blake Byers
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$247.25 M (USD)
in 3 rounds
-
Latest Funding Round
$45 M (USD), Series B
Oct 20, 2025
-
Investors
Kleiner Perkins
& 14 more
-
Employee Count
9
as on Oct 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NewLimit
NewLimit offers a comprehensive portfolio of products and services, including Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program.
Medicines that restore youthful function in aging cells via reprogramming.
Program targeting aging immune systems for functional restoration.
Interventions to rejuvenate liver cells in aging processes.
People of NewLimit
Unlock access to complete
Unlock access to complete
Funding Insights of NewLimit
NewLimit has successfully raised a total of $247.25M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $45 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NewLimit
NewLimit has secured backing from 15 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kleiner Perkins, Khosla Ventures and Dimension Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology and defense sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in early-stage tech startups
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by this venture capital firm.
|
Locked | Locked | Locked |
Investor details for NewLimit
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NewLimit
Investment portfolio details for NewLimit
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NewLimit
Detailed financials for NewLimit
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Newlimit Comparisons
Peer comparison for NewLimit
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NewLimit
NewLimit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, CatSci and NIH, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to pharmaceutical clients worldwide.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
Detailed competitors of NewLimit
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Newlimit
Complete news archive for NewLimit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NewLimit
NewLimit was founded in 2022 and raised its 1st funding round 1 year after it was founded.
NewLimit is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
NewLimit is a funded company, having raised a total of $247.25M across 3 funding rounds to date.
As of Oct 31, 2024, the latest employee count at NewLimit is 9.
Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension. It focuses on restoring youthful function in old cells by reprogramming the epigenome. The company leverages technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify epigenetic features of aging and discover interventions for rejuvenation. Its initial programs target the aging liver, immune, and vascular systems, with the long-term goal of significantly extending human healthspan through medicines for diseases associated with aging.
NewLimit's top competitors include Evotec, Crown Bioscience and NIH.
NewLimit offers Epigenetic Reprogramming Medicines, Immune System Rejuvenation Program, and Liver Function Restoration Program.
NewLimit has 15 investors. Key investors include Kleiner Perkins, Khosla Ventures, Dimension Venture Partners, Founders Fund, and Eric Schmidt.